Biopharma · us
AbbVie to Spend $10.9 Billion to Acquire Apogee as Immunotherapy Race Shifts Toward “Fewer Injections”
The acquisition pushes large pharmaceutical companies’ immunology strategies from extending single blockbuster drugs toward the next round of clinical competition in long-acting antibodies, combination designs, and respiratory inflammatory diseases.
In chronic inflammatory diseases such as atopic dermatitis and asthma, efficacy is no longer the only battleground. Whether patients can receive fewer injections, how long disease control can be maintained, and whether skin symptoms and itching can be improved at the same time are gradually becoming core selling points for the next generation of immunology drugs. AbbVie’s agreement to acquire Apogee Therapeutics for about $10.9 billion is a bet on precisely this direction.
AbbVie announced on June 22 that it will acquire all outstanding shares of Apogee for $135.11 per share in cash. The boards of both companies have unanimously approved the transaction, which is expected to close in the third quarter of 2026, but remains subject to approval by Apogee shareholders and relevant regulatory approvals. According to the companies, the deal will strengthen AbbVie’s existing immunology portfolio and accelerate its move into clinical development for respiratory diseases.
The central asset in the transaction is zumilokibart, also known as APG777. It is an extended half-life, subcutaneously injected monoclonal antibody targeting IL-13 signaling, currently being developed primarily for atopic dermatitis. IL-13 is a key cytokine in type 2 inflammatory responses and is associated with impaired skin barrier function, itching, and multiple allergic inflammatory diseases. As a result, competition around this pathway has long been about more than whether a drug can reduce inflammation; it is also about who can offer more convenient long-term control.
Citing Apogee’s Phase 2 clinical data, AbbVie said that among atopic dermatitis patients treated with zumilokibart, about two-thirds achieved significant skin improvement at 16 weeks, with progress also seen in itching and overall disease control. Longer-term data support the concept of maintenance dosing once per quarter or twice per year. However, this information comes from company announcements and is not sufficient to replace complete peer-reviewed data and results from large late-stage trials. For chronic diseases, long-term safety, rebound after treatment discontinuation, and differences in response across populations will all affect real-world clinical value.
Apogee’s appeal is not limited to a single drug candidate. Its pipeline also includes APG273, a long-acting combination of zumilokibart and the anti-TSLP antibody APG333 that is being developed for asthma. TSLP sits further upstream in respiratory inflammatory responses and is viewed as one of the signals that initiates responses across multiple immune cells. If paired with an IL-13 inhibition strategy, it could in theory broaden control of type 2 inflammatory asthma, but clinical trials are still needed to prove whether its efficacy and safety are sufficient to support this combination design.
For AbbVie, the transaction continues its strategy of using immunology as a core pillar. The company has long relied on major immunology drugs to establish its market position, and now needs to identify the next group of clinical assets that can take up growth across dermatology, rheumatology, gastrointestinal, and respiratory diseases. AbbVie also said the acquisition is expected to be accretive to adjusted diluted earnings per share starting in 2032. That also indicates the timeline for market returns is not short, with clinical development and commercialization risks still spanning many years.
The scientific signal from this acquisition is clear: treatment for chronic immune diseases is moving from “whether it works” toward “whether it can be long-acting, precise, and sustainable.” But what $10.9 billion buys is still an unfinished promise. Zumilokibart must prove in late-stage trials that early efficacy can be sustained, and APG273 must also find a clear positioning in the crowded and highly heterogeneous asthma field. Until then, the transaction looks more like AbbVie buying an early ticket to the next-generation immunotherapy race.